According to filings with the U.S. Securities and Exchange Commission, APRINOIA Therapeutics is raising $50,000,000.00 in new funding. About APRINOIA Therapeutics: Aprinoia Therapeutics is dedicated to establish a drug discovery and early development company that is based on innovation and scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: 1. Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and 2. Novel therapies to improve the treatment of human neurological conditions. We are a clinical stage biotech company committed to protecting patients’ brain health and changing outcomes for a broad range of neurodegenerative diseases through best-in-class diagnostic tools and novel therapies. Our name, APRINOIA, merges the Latin word for sunlight, “apricum,” with the Greek suffix for the mind, “noia.” Our name reflects our mission—to shed light on ways to better diagnose and treat these dreaded neurodegenerative disorders with a vision that these novel diagnostic tools together with targeted therapies will offer a better future for our patients.

To learn more about APRINOIA Therapeutics, visit http://aprinoia.com/

Contact:
Mark Shearman, Chief Executive Officer
617-225-4415
https://www.linkedin.com/in/marksshearman/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.